Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

saracatinib (AZD0530)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

Src kinase inhibitor, FAK inhibitor

Related drugs:

SRC T341I	Cholangiocarcinoma	SRC T341I	Cholangiocarcinoma	AZD0530 Resistant: D – Preclinical AZD0530 Resistant : D	AZD0530 Resistant: D – Preclinical AZD0530 Resistant : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH2 R172K	Cholangiocarcinoma	IDH2 R172K	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH2 mutation	Cholangiocarcinoma	IDH2 mutation	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
EGFR amplification	Oral Cancer	EGFR amplification	Oral Cancer	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D